Repligen Announces FDA Advisory Committee Date for SecreFlo NDA

Repligen Corporation

today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application for SecreFlo™ for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis. Publicly available briefing documents for the meeting are expected to be posted to the FDA website two business days in advance of the Committee meeting.